Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (VOYAGE)
Sponsor: Clinical Trials Resource Group, LLC
Listed as NCT04708145, this PHASE4 trial focuses on Diabetic Retinopathy and remains completed. Sponsored by Clinical Trials Resource Group, LLC, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Sep 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Mar 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Trials Resource Group, LLC
- Greater Houston Retina Research
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .